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An Ointment to Treat Leishmaniasis 
In this issue, a group o f Israe li resea rchers repo rt the first topical 
trea tm ent fo r cutaneous leishmanias is. Previo us trea tm ents o f this 
protozoan skin disease are va ri abl y effec ti ve, have potentiall y se-
rious side effects, and must o ften be administered in hospitals. 
J oseph EI-On o f Ben Gurion Uni versity of the N egev in Beer-
Sheva, Rita Livshin , Zvi Even- Paz, and Louis Weinrauch of He-
brew University Hadassa h Medical School in Jerusa lem, and David 
H amburger o f T eva Pharm aceuti cals in Jerusalem trea ted 67 pa-
tients infected by Leishmar-/ia maj or, the cause of cutaneous leish-
m anias is in the Old Wo rld, w ith an o intment containing paro-
m o m ycin and m eth ylbenzethonium chlo ride. Within 10 days of 
treatment, the les ions in 72% of the patients were free o f the 
leishmania protozoa and 94% of the treated lesions healed w itho ut 
scarrin g. 
T he clinica l study, says Weinrauch, follows 3 yea rs of wo rk 
w ith the new trea tment, both in vitro and in animals. In these 
studies, th e inves tigators learned that neither of the 2 compounds 
th at together kill the leishmania paras ite is effecti ve alone. Wein-
rauch no tes, "There is no correlation between in vi tro and in vivo 
wo rk ." Since the co mbination of paro mo m ycin and m eth yl ben-
zeth onium chl o ride is ineffecti ve aga inst the protozoa in vitro, 
ye t is effecti ve in vivo. The dru gs work by destroying the mem-
brane o f th e paras ite witho ut damaging the hos t cells. 
Weinrauch and his colleagues are continu ing to stu dy the cl in-
ical spectrum of the o intment, tes ting to see ifit is equall y effective 
aga inst Leishlllaniasis 111 exiaca II a amazollensis and Leishlllan iasis ae-
thiopica. 
N ear-Ultraviolet Light and Skin C ancer 
Fo r yea rs, clini cal investiga to rs have debated wheth er nea r-ultra-
vio let lig ht, UV A, is ca rcinogeni c even though it clea rl y coul d 
not be as stron g a ca rcinogen as UV B. Since there is 20 tim es 
m o re UV A th an UVB in sunlig ht, UV A might still playa role 
in inducing skin cancer despite the fact that it may be onl y mildly 
ca rcinogeni c. N ow, repo rting in this issue, Paul Strickland o f The 
J o hns H o pkins Uni versity Medi ca l Schoo l find s th at UV A is 
indeed a ca rcinogen . 
Stri ckland exposed Senca r mice, w hich are hi ghl y susceptible 
to skin ca ncer , to UV A fo r 12 to 18 hours a day. Within 68 
weeks, th e anim als develo ped skin cancer. Since he rigorously 
filtered UVB from the li g ht the animals were exposed to, Strick-
land is quite sure that it w as in fa ct UV A th at ca used the anim als' 
tu m ors. The UV A is a mild ca rcinogen, however, co mpared w ith 
U VB . When Stri ckland ex posed Senca r mi ce to a mix ture of 
U V A and UVB just 3 times per week, the animals developed 
skin tumo rs within 23 weeks. 
In addition to answerin g the questi on o f w hether UV A is reall y 
ca rcinogenic, Stri ckl and 's res ul ts have cl inica l significance. M any 
people are exposed to m os tl y UV A light in tannin g machines in 
their attempts to minimize their chances of develo ping skin ca n-
cer. A few years ago, tannin g booths switched fro m UVB to 
UV A li ght machines, although much hig her doses o f UVA are 
needed to induce tanning. Yet since UV A is ca rcinogenic, patrons 
of tanning booths mig ht still be pl acing themselves at risk for 
skin cancer. These people may not be as safe as they have been 
led to believe. Also, most sunscreens in w ide usage are des igned 
to block UVB , but no t UVA . Alth oug h this design of sunscreens 
" is rati onal,' Strickland says, it might also be impo rtant to block 
UV A, especiall y fo r fa ir-skinn ed people and th ose from mela-
no ma-p rone fa miles. 
T he exact contribution of UVA to sunlig ht- induced skin ca ncer 
rem ains to be so rted out. But it now is cl ea r that the role of U V A 
is indu cing skin cancer ca nn ot be discounted. 
D etecting AIDS by M eans of a Surface Antigen 
Befo re the HTL V fII an tibody test fo r AIDS becam e ava ilable, 
Carole Berger and her colleag ues at Columbia Uni ve rsity bega n 
lookin g fo r a way of de tectin g the AI DS virus throug h cel l sur f.1ce 
m arkers. N ow, Berger, Al vin Friedm an-Kien, Mathew I i-
Franco, T ho m as Rehlc, Ri chard Ostreicher, Robert Kn o bler, 
Samuel D ono fri o, Linda Laubenstein , and Richard Edel son repo rt 
that they SLI cceeded in develo ping a test that ca n indi ca te w hether 
pa tients have AIDS. T he tes t, Berger sugges ts, ca n supplement 
the HT LV III antibody tes t in certain cases w here di agnoses are 
in do ubt. 
Berger bega n th e stud y, she says, beca use she and her associates 
wanted to see if a marker fo r abno rm al lym phocy tes th at appea rs 
o n cell s from lympho ma patients also occu rs on the lymph ocy tes 
of AIDS patients. This marker, detected by a monoclonal anti-
bod y, occurs o nly on malignant T4 + lymphocytes fro m the can-
cer patients. The in ves ti ga to rs decided to tes t T cells fro m AIDS 
patients because T cells are ta rgets fo r the AIDS vi ru s. 
T he g ro up lea rned that about half of all AI DS patients have 
T4 + cells th at express the abno rm al surface antigen. As AIDS 
progresses and patients lose more and mo re of their T cells, the 
number of cell s ex pressing this marker diminishes. T hese fi ndi ngs 
confirm the o bserva tion that th e presence of this marker is lin ked 
to the AIDS in fect ion, accordin g to Berger. 
T he AIDS patients w hose cells do not express detectable amounts 
of th e m arker so metim es have few T4 + cells as a consequence o f 
th eir disease. In general , Berger and her coll eagues find , th ose 
patients w hose cells have the marker are in the ea rlier stages of 
the disease. Yet there are so me patients in the ea rl y stages w ho 
apparentl y have T4 + cell s that do no t express the marker. These 
fi ndings most likely reflect the fac t th at the AIDS viruses are 
heterogeneous. N o t all va riants of the virus, ap parentl y, induce 
the expression of the marker. 
The Columbia Uni versity resea rchers are now using this ab-
no rm al T cell sur face antigen tes t in cases w here they are not 
certain o f a diagnosis of AIDS . In parti cul ar, they frequentl y fi nd 
that AIDS in children is difficul t to diagnose and the new tes t is 
turnin g out to be a useful cl ini ca l tool. 
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Understanding Vitiligo Photo chemotherapy 
Although photochemotherapy with 8-methoxypsoralen can be 
an effective treatment for vitiligo, not all patients res pond. [n 
particular, John Kenney and his colleagues at Howard University 
Hospital's Vitiligo Center find that only about 60% of their pa-
tients are aided by this therapy. The difference between re-
sponders and nonresponders, Kenney and his colleagues reasoned, 
might be that different patients abso rb different amounts of the 
drug. So Kenney, Siba Chakrabarti, Rebat Halder, Beverly John-
son, Harold Minus, and Tapas Pradhan developed a reliable assay 
for 8-methoxypsoralen in blood and tissue samples. They report 
their results in this issue. 
The method employs thin-layer chromatography and scannin g 
fluorom etry and provides more reliable estimates of 8-methox-
ypsoralen concentrations in the blood than were previously re-
ported by others using different methods. For that reason, Kenney 
and his associates propose that their method might be more sen-
sitive than others . 
When the investigators assayed peak drug concentrations in 
patients, they found that the amount of drug in the blood varied 
widely-from 2 ng per ml to more than 3000 ng per ml. Patient s 
with low levels of the drug in the blood also tended to have low 
levels in the sk in. Thus it is quite possible that those patients w h o 
fail to response to the drug also fa il to accumulate it. 
Kenney and his associates also looked into the matter of the 
accu mulation of 8-methoxypsoralen in the eye because there are 
reports that the drug in combinat ion with UV light can lead t o 
ca taracts. Using guinea pigs as their model , they found that the 
drug accumulates to a significant degree in the retina, lens, aqueous 
humor, and vitreous gel, and remains there for 24 hours. These 
results, they note, indicate that the eyes of patients must be shielded 
from exposure to sunlight for 24 hours after photochemotherapy. 
The investigators conclude that it might still be possible to treat 
previously nonresponding vitilego patients with photochemo_ 
therapy. However, a different dosage or method of drug delivery 
may be required to assure that, in these patients, the dru g actually 
accumulates in high enough concentration in the skin. 
